bi 3031185
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 8, 2024 (NCT06255340)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
GRIA1 modulator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07211425 | Phase 1 | Oct 8, 2025 | Boehringer Ingelheim |
| NCT07001475 | Phase 1 | Aug 12, 2025 | Boehringer Ingelheim |
| NCT06916702 | Phase 1 | Apr 7, 2025 | Boehringer Ingelheim |
| NCT06255340 | Phase 1 | Mar 8, 2024 | Boehringer Ingelheim |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 4 | 4 | 1 | 2024 |
1 organizations
Page 1 / 1